Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Period: Six months ended June 30, 2024
Business Overview: Inmune Bio is a clinical-stage biotechnology company focused on developing therapies for diseases involving innate immune dysfunction. Its two primary platforms are the DN-TNF platform (targeting Alzheimer's disease, treatment-resistant depression, and cancer) and the Natural Killer Cell Priming platform (INKmune, targeting hematologic malignancies and solid tumors). The company has no approved products and generates minimal revenue.
Key Financial Metrics
| Metric (in thousands) | Six Months Ended June 30, 2024 | Six Months Ended June 30, 2023 |
|---|---|---|
| Revenue | $14 | $84 |
| Net Loss | $(20,771) | $(13,037) |
| Net Loss Per Share (Basic & Diluted) | $(1.11) | $(0.73) |
| Operating Expenses | $20,896 | $12,918 |
| Research & Development (R&D) | $15,746 | $8,281 |
| General & Administrative (G&A) | $5,150 | $4,637 |
| Cash and Cash Equivalents (End of Period) | $31,069 | $47,825 |
| Net Cash Used in Operating Activities | $(15,362) | $(4,315) |
| Net Cash Provided by Financing Activities | $10,497 | $0 |
| Total Debt (Current Portion) | $4,979 | $9,921 |
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by approximately $7.7 million year-over-year, driven primarily by a $7.5 million increase in R&D expenses and a $0.5 million increase in G&A expenses.
- R&D Expense Surge: R&D expenses rose from $8.3 million to $15.7 million. This increase is attributed to higher costs for the Alzheimer's clinical program ($6.5 million increase) and the INKmune clinical programs ($1.4 million increase), partially offset by increased accrued R&D rebates.
- Debt Reduction: The company repaid $5.0 million of its term loan during the period, reducing the current portion of long-term debt from $9.9 million to $5.0 million.
- Financing Activity: Unlike the prior period, the company raised approximately $15.5 million in gross proceeds through registered direct offerings and At-The-Market (ATM) sales in the first half of 2024.
- Cash Burn: Net cash used in operating activities increased significantly from $4.3 million to $15.4 million, reflecting the higher operational burn rate.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With cash of $31.1 million and a projected operating burn rate, the company estimates it will have insufficient liquidity to sustain operations for one year following the issuance of these financial statements.
- Capital Needs: The company is actively evaluating financing strategies, including public or private equity sales, debt financing, government grants, collaborations, or asset divestment. There is no assurance that additional funding will be available on favorable terms.
- Clinical Milestones:
- Alzheimer's (XPro1595): The Phase II trial enrollment of 201 patients is expected to be complete by mid-year 2024. Top-line cognition data is expected six months after the last patient is enrolled.
- Prostate Cancer (INKmune): The Phase I/II trial is on track with recruitment. Top-line data is expected in the second half of 2025.
- Depression (XPro1595): The company expects to receive authorization to initiate a Phase II trial in the second half of 2024.
- Legal Contingency: The company reclassified $799,000 of common stock as temporary equity due to shares inadvertently sold under an expired registration statement in July 2023. While no claims have been made, the company faces potential rescission claims or regulatory penalties.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for when cash reserves are projected to be depleted and the status of any new financing agreements.
- Phase II Alzheimer's Trial: Monitor the completion of patient enrollment and the timeline for the release of top-line EMACC data.
- Debt Covenants: Review the terms of the remaining $5.0 million term loan maturing in January 2025, including interest rates and prepayment penalties.
- Legal Exposure: Track any developments regarding the potential rescission claims related to the July 2023 ATM offering.
- R&D Tax Credits: Confirm the receipt of the $2.475 million Australian R&D tax credit reimbursement noted as received in July 2024 (subsequent to the period end).